Invivo Therapeutics Holdings Stock Beta
| NVIVDelisted Stock | USD 1.38 0.07 5.34% |
InVivo Therapeutics Holdings fundamentals help investors to digest information that contributes to InVivo Therapeutics' financial success or failures. It also enables traders to predict the movement of InVivo Stock. The fundamental analysis module provides a way to measure InVivo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to InVivo Therapeutics stock.
InVivo |
InVivo Therapeutics Holdings Company Beta Analysis
InVivo Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current InVivo Therapeutics Beta | 0.66 |
Most of InVivo Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InVivo Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, InVivo Therapeutics Holdings has a Beta of 0.658. This is 23.49% lower than that of the Health Care Equipment & Supplies sector and 52.66% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
InVivo Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InVivo Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of InVivo Therapeutics could also be used in its relative valuation, which is a method of valuing InVivo Therapeutics by comparing valuation metrics of similar companies.InVivo Therapeutics is currently under evaluation in beta category among its peers.
As returns on the market increase, InVivo Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding InVivo Therapeutics is expected to be smaller as well.
InVivo Fundamentals
| Return On Equity | -0.98 | |||
| Return On Asset | -0.54 | |||
| Current Valuation | (7.59 M) | |||
| Shares Outstanding | 3.11 M | |||
| Shares Owned By Insiders | 0.02 % | |||
| Shares Owned By Institutions | 3.44 % | |||
| Number Of Shares Shorted | 17.63 K | |||
| Price To Earning | (1.90) X | |||
| Price To Book | 0.1 X | |||
| EBITDA | (9.8 M) | |||
| Net Income | (9.33 M) | |||
| Cash And Equivalents | 13.03 M | |||
| Cash Per Share | 9.36 X | |||
| Total Debt | 949 K | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 5.64 X | |||
| Book Value Per Share | 2.87 X | |||
| Cash Flow From Operations | (10.13 M) | |||
| Short Ratio | 0.91 X | |||
| Earnings Per Share | (3.28) X | |||
| Target Price | 37.5 | |||
| Beta | 0.66 | |||
| Market Capitalization | 995.92 K | |||
| Total Asset | 18.82 M | |||
| Retained Earnings | (248.62 M) | |||
| Working Capital | 15.13 M | |||
| Current Asset | 20.74 M | |||
| Current Liabilities | 3.31 M | |||
| Z Score | -18.62 | |||
| Net Asset | 18.82 M |
About InVivo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze InVivo Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InVivo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InVivo Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |